Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith A Perez

Showing results (91-100 of 324) with videos related to

Pageof 33
Sort By:
Breast Cancer Research : BCR|May 1, 2015
Erratum: Dual HER2 blockade: preclinical and clinical dataTejal A Patel, Bhuvanesh Dave, Angel A Rodriguez, et al.
Breast Cancer Research : BCR|May 1, 2015
Dual HER2 blockade: preclinical and clinical dataTejal A Patel, Bhuvanesh Dave, Angel A Rodriguez, et al.
Cancer|April 16, 2013
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831Jennifer A Crozier, Alvaro Moreno-Aspitia, Karla V Ballman, et al.
Breast Cancer Research and Treatment|May 2, 2012
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)Tianhong Li, Mengye Guo, William J Gradishar, et al.
Cancer Journal (Sudbury, Mass.)|September 22, 2015
Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access StudyDenise A Yardley, Ian E Krop, Patricia M LoRusso, et al.
Breast Cancer Research : BCR|June 3, 2014
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancerEdith A Perez, Sara A Hurvitz, Lukas C Amler, et al.
Clinical Medicine. Oncology|September 6, 2011
Increased incidence of loco-regional recurrences among african american women with terminal stage breast cancerGerardo Colón-Otero, Sherry King, Vandelyn Smith, et al.
Frontiers in Immunology|July 26, 2021
Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1Jing Yang, Edith A Perez, Changchun Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2008
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Lori J Goldstein, Anne O'Neill, Joseph A Sparano, et al.
Clinical Breast Cancer|September 19, 2015
N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing TherapyJennifer A Crozier, Pooja P Advani, Betsy LaPlant, et al.
Pageof 33

Showing results (91-100 of 324) with videos related to

Sort By:
Pageof 33
Breast Cancer Research : BCR|May 1, 2015
Erratum: Dual HER2 blockade: preclinical and clinical dataTejal A Patel, Bhuvanesh Dave, Angel A Rodriguez, et al.
Breast Cancer Research : BCR|May 1, 2015
Dual HER2 blockade: preclinical and clinical dataTejal A Patel, Bhuvanesh Dave, Angel A Rodriguez, et al.
Cancer|April 16, 2013
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831Jennifer A Crozier, Alvaro Moreno-Aspitia, Karla V Ballman, et al.
Breast Cancer Research and Treatment|May 2, 2012
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)Tianhong Li, Mengye Guo, William J Gradishar, et al.
Cancer Journal (Sudbury, Mass.)|September 22, 2015
Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access StudyDenise A Yardley, Ian E Krop, Patricia M LoRusso, et al.
Breast Cancer Research : BCR|June 3, 2014
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancerEdith A Perez, Sara A Hurvitz, Lukas C Amler, et al.
Clinical Medicine. Oncology|September 6, 2011
Increased incidence of loco-regional recurrences among african american women with terminal stage breast cancerGerardo Colón-Otero, Sherry King, Vandelyn Smith, et al.
Frontiers in Immunology|July 26, 2021
Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1Jing Yang, Edith A Perez, Changchun Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2008
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Lori J Goldstein, Anne O'Neill, Joseph A Sparano, et al.
Clinical Breast Cancer|September 19, 2015
N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing TherapyJennifer A Crozier, Pooja P Advani, Betsy LaPlant, et al.
Pageof 33